{"organizations": [], "uuid": "18d6fe5034e6e1dbd67aec2376d452cdc733e3ec", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://images.wsj.net/im-3728/social", "site_section": "https://www.wsj.com/news/business", "section_title": "Business &amp; Finance News - Wall Street Journal", "url": "https://www.wsj.com/articles/orexigen-bankruptcy-shows-difficulty-of-marketing-weight-loss-drugs-1520886182", "country": "US", "domain_rank": 387, "title": "Orexigen Bankruptcy Shows Difficulty of Marketing Weight-Loss Drugs", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.948, "site_type": "news", "published": "2018-03-12T23:23:00.000+02:00", "replies_count": 0, "uuid": "18d6fe5034e6e1dbd67aec2376d452cdc733e3ec"}, "author": "Peter Loftus", "url": "https://www.wsj.com/articles/orexigen-bankruptcy-shows-difficulty-of-marketing-weight-loss-drugs-1520886182", "ord_in_thread": 0, "title": "Orexigen Bankruptcy Shows Difficulty of Marketing Weight-Loss Drugs", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Drugmaker Orexigen Therapeutics Inc. filed for bankruptcy protection on Monday and plans to sell itself, after failing to find a profitable market for its weight-loss treatment Contrave.\nThe move underscores the difficulties the pharmaceutical industry has encountered in finding a safe and effective diet drug in the two decades since a drug that was part of the popular “fen-phen” treatment was pulled from the market because it was causing heart problems in patients.\n...  ", "external_links": [], "published": "2018-03-12T23:23:00.000+02:00", "crawled": "2018-03-12T23:02:45.007+02:00", "highlightTitle": ""}